Home About Us Research Pipeline Newsroom Contact Us

Hepatitis C is a global disease and it is estimated that over 3 million people in the US are infected with the virus, many of whom donít know it yet. The disease is named for the target organ which the Hepatitis C virus attacks Ė hepatic (liver) cells. It is the major cause of cirrhosis of the liver, liver failure, and primary liver cancer (hepatocellular carcinoma). It is also responsible for the majority of liver transplants. The current treatment for Hepatitis C has severe side effects and the majority of symptomatic patients are not helped by the treatment. iTherX scientists are studying the molecular mechanisms involved in the first step in hepatitis C virus infection: entry into the liver cell. Our insights have enabled us to pioneer drugs which block viral entry: HCV Entry Inhibitors. >>>read more

WHAT’S NEW?

November 6, 2013
INVESTIGATORS REPORT RESULTS OF PHASE 1B STUDY OF ITHERX FIRST IN CLASS HEPATITIS C ENTRY INHIBITOR ITX 5061 IN LIVER TRANSPLANT PATIENTS
-- iTherX, a pharmaceutical company dedicated to discovering and developing a new class of therapeutics for hepatitis C, announced that investigators from the University of Birmingham UK...

>>>more
 
Copyright ©2008 iTherX, Inc. All rights reserved.